Skip to main content

Table 6 Responsiveness of PROMIS Fatigue Short Form 6a at months 3 and 6

From: Psychometric assessment of the PROMIS Fatigue Short Form 6a in women with moderate-to-severe endometriosis-associated pain

Time Sample N Mean (SD) t-value (p-value) Effect size (Cohen’s d)b
Baseline Post-baselinea Change (SD)
Month 3 Total Sample 728 63.2 (7.5) 57.0 (9.7) −6.2 (9.8) 17.12 (< 0.0001) −0.83
Placebo 314 62.4 (7.4) 58.2 (9.7) −4.2 (9.3) 8.02 (<.0001) −0.57
150 mg 216 64.0 (7.8) 57.4 (9.5) −6.7 (10.0) 9.79 (<.0001) −0.85
200 mg 198 63.6 (7.3) 54.6 (9.5) −9.0 (9.9) 12.90 (<.0001) −1.25
Month 6 Total Sample 577 63.1 (7.5) 56.3 (10.1) −6.8 (10.4) 15.76 (< 0.0001) −0.91
Placebo 246 62.5 (7.7) 58.3 (10.0) −4.2 (9.8) 6.73 (<.0001) −0.55
150 mg 170 63.6 (7.7) 56.6 (9.4) −7.0 (9.9) 9.24 (<.0001) −0.91
200 mg 161 63.5 (7.2) 52.9 (10.0) −10.6 (10.7) 12.64 (<.0001) −1.48
  1. PROMIS Indicates Patient-Reported Outcome Measurement Information System, SD Half standard deviation, SEM Standard error of the mean
  2. Paired t-test
  3. aMonth 3 or month 6
  4. bCalculated as mean change / SD for baseline score
\